News
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...
Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...
Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it is a Buy.
Sanofi plans to initiate a Phase 1 study of KT-485 next year. It has also decided to exercise its participation election right for the IRAK4 target. As per the agreement, Kymera achieved a $20 ...
Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 ...
Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP ...
Adagene Inc. announced that Sanofi will invest up to $25 million and exercise its option for a third SAFEbody discovery program, furthering their strategic partnership. The investment will fund ...
Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.
Regeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid June 20, 2025 — 01:41 am EDT Written by RTTNews.com for RTTNews -> ...
(RTTNews) - Sanofi S.A. (SNYNF,SNY) said that the U.S. Food and Drug Administration has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of ...
(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results